INVITED RESEARCH HIGHLIGHT
Year : 2014  |  Volume : 16  |  Issue : 4  |  Page : 568-569

Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib


Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, USA

Correspondence Address:
Dr. Himisha Beltran
Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1008-682X.127822

Rights and Permissions

Prostate cancer is a leading cause of cancer death in men. Despite recent advances in our understanding and treatment of advanced disease, no systemic therapy is curative and new therapies are needed. Targeting angiogenesis is an attractive therapeutic strategy, as angiogenic pathways are upregulated in prostate tumors similar to other malignancies due to imbalance of pro- and anti-angiogenic factors secreted by tumor, endothelial and stromal cells and increased neovasculature. [1] Vascular endothelial growth factor (VEGF) is the most well-characterized pro-angiogenenic factor, with several small molecule inhibitors (sunitinib, sorafenib, pazopanib, axitinib, others), antibodies (bevacizumab) and other drugs that target the VEGF pathway approved and/or in development for the treatment of a wide range of tumor types.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2227    
    Printed62    
    Emailed0    
    PDF Downloaded354    
    Comments [Add]    
    Cited by others 1    

Recommend this journal